These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 24040873)
1. The role of oral antidiabetic agents and incretin mimetics in type 2 diabetic patients with non-alcoholic fatty liver disease. Gouni-Berthold I; Papanas N; Maltezos E Curr Pharm Des; 2014; 20(22):3705-15. PubMed ID: 24040873 [TBL] [Abstract][Full Text] [Related]
2. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499 [TBL] [Abstract][Full Text] [Related]
3. Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease. Nakouti T; Karagiannis AK; Tziomalos K; Cholongitas E Curr Vasc Pharmacol; 2015; 13(5):649-57. PubMed ID: 25412688 [TBL] [Abstract][Full Text] [Related]
4. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. Dougherty JA; Guirguis E; Thornby KA Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083 [TBL] [Abstract][Full Text] [Related]
5. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Ranjbar G; Mikhailidis DP; Sahebkar A Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578 [TBL] [Abstract][Full Text] [Related]
7. The role of incretin hormones and glucagon in patients with liver disease. Junker AE Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096 [TBL] [Abstract][Full Text] [Related]
8. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. Budd J; Cusi K Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726 [TBL] [Abstract][Full Text] [Related]
9. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. Carbone LJ; Angus PW; Yeomans ND J Gastroenterol Hepatol; 2016 Jan; 31(1):23-31. PubMed ID: 26111358 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors. Ohki T; Isogawa A; Toda N; Tagawa K Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659 [TBL] [Abstract][Full Text] [Related]
11. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616 [TBL] [Abstract][Full Text] [Related]
12. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. Kumar J; Memon RS; Shahid I; Rizwan T; Zaman M; Menezes RG; Kumar S; Siddiqi TJ; Usman MS Dig Liver Dis; 2021 Jan; 53(1):44-51. PubMed ID: 32912770 [TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Cusi K Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131 [TBL] [Abstract][Full Text] [Related]
16. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis? Doumas M; Imprialos K; Stavropoulos K; Athyros VG Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. Yabiku K Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104 [TBL] [Abstract][Full Text] [Related]
18. GLP-1 receptor agonists in NAFLD. Petit JM; Vergès B Diabetes Metab; 2017 Apr; 43 Suppl 1():2S28-2S33. PubMed ID: 28431668 [TBL] [Abstract][Full Text] [Related]
19. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. Liu Y; Wei R; Hong TP World J Gastroenterol; 2014 Jul; 20(27):9090-7. PubMed ID: 25083081 [TBL] [Abstract][Full Text] [Related]
20. Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. Blaslov K; Bulum T; Zibar K; Duvnjak L World J Gastroenterol; 2014 Jun; 20(23):7356-65. PubMed ID: 24966606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]